Drugs (Prices Control) Order: Govt's DPCO, 2013 implementation saves public's Rs 12447 cr
NPPA has issued 2083 demand notices for over Rs 6406 cr in matters of overcharging consumers; over Rs 960 cr deposited by companies while over Rs 4032 cr under litigation
The government has saved over Rs 12447 cr per annum to the public through drug price fixation after implementation of the DPCO, 2013, a government release said quoting DV Sadananda Gowda, Minister for Chemicals & Fertilizers. The minister in a written reply today informed the Lok Sabha, the release said.
Gowda also informed the house that 2083 demand notices (including suo-moto deposits) have been issued to pharmaceutical companies since the inception of the NPPA for overcharging consumers on the sale of formulations at prices above the ceiling price notified by the NPPA.
Demand Notices have been issued for an amount of Rs 6406.33 cr, the release said. Amount to the tune of Rs 960.38 cr has been deposited by the companies to the Government while an amount of over Rs 4032 cr is under litigation, the release said.
The National Pharmaceutical Pricing Authority (NPPA) fixes the ceiling price of scheduled formulations adopted from the National List of Essential Medicines (NLEM) and new drugs as per the provisions of para 4, 5 and 6 of the Drugs (Prices Control) Order, 2013 (DPCO, 2013).
The prices of the non-scheduled formulation are monitored so that their MRP is not increased by more than 10% of MRP during the preceding twelve months, the release said quoting the Minister.
NPPA fixed the ceiling prices of 530 scheduled formulations under NLEM, 2011. The details of reduction in prices of scheduled formulations affected under the DPCO, 2013 as compared to the highest price prevailed prior to the price fixation is as below:
% reduction wrt max price No. of drugs
0<= 5% 80
35<=40% 3 4
Above 40% 126
NPPA fixed prices of 106 Anti-diabetic and Cardiovascular drugs, the release said. It has also fixed ceiling price of Cardiac Stents, orthopedic knee implants, the release said.
See Zee Business Live TV Streaming Below:
The regulator also capped the Trade Margin of non-scheduled formulations of 42 select Anti-cancer medicines under 'Trade Margin Rationalization' approach as a Pilot for proof of concept, wherein price of above 500 brands of medicines were reduced upto 90%, the release said.
Get Latest Business News, Stock Market Updates and Videos; Check your tax outgo through Income Tax Calculator and save money through our Personal Finance coverage. Check Business Breaking News Live on Zee Business Twitter and Facebook. Subscribe on YouTube.